Clinical Trials Browser

Phase 2 × Has results × Parkinson Disease 4, Autosomal Dominant Lewy Body × Clear all

NCT04191135 2026-03-03

KEYLYNK-009

Phase 2 Completed

462 enrolled 30 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Triple Negative Breast Neoplasms

NCT03993353 2026-02-12

Tadalafil and Pembrolizumab in Recurrent or Metastatic Head and Neck Cancer

Phase 2 Completed

7 enrolled 14 charts

GastrointestinalHead & Neck

Pyridoxine-dependent epilepsy, Parkinson Disease 4, Autosomal Dominant Lewy Body, Squamous Cell Carcinoma of Head and Neck, Carcinoma, Esophageal Neoplasms, Head and Neck Neoplasms, Mouth Neoplasms, Neoplasm Metastasis, Neoplasms

NCT04428151 2025-12-04

LEAP-009

Phase 2 Completed

408 enrolled 17 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Squamous Cell Carcinoma of Head and Neck

NCT04704219 2025-12-03

KEYNOTE-B61

Phase 2 Completed

160 enrolled 14 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Renal Cell

NCT03797326 2025-11-17

LEAP-005

Phase 2 Completed

611 enrolled 27 charts

BreastCNSGastrointestinalGynecologic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Biliary Tract Neoplasms, Glioblastoma, Ovarian Neoplasms, Pancreatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Triple Negative Breast Neoplasms

NCT03322540 2025-08-22

Pembrolizumab Plus Epacadostat vs Pembrolizumab Plus Placebo in Metastatic Non-Small Cell Lung Cancer (KEYNOTE-654-05/ECHO-305-05)

Phase 2 Completed

154 enrolled 14 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT04116073 2025-07-29

INCMGA00012 in Patients With Previously Treated Unresectable or Metastatic Adenosquamous Pancreatic or Ampullary Cancer

Phase 2 Completed

25 enrolled 12 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body

NCT03631784 2025-03-25

KEYNOTE-799

Phase 2 Completed

216 enrolled 15 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung

NCT02787005 2024-11-21

KEYNOTE-199

Phase 2 Completed

388 enrolled 23 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body

NCT03631407 2024-11-21

MK-7690-046

Phase 2 Completed

41 enrolled 20 charts

Gastrointestinal

Parkinson Disease 4, Autosomal Dominant Lewy Body, Spinocerebellar Degenerations, Colorectal Neoplasms

NCT02702414 2024-09-04

KEYNOTE-224

Phase 2 Completed

156 enrolled 17 charts 1 FDA

Gastrointestinal

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Hepatocellular

NCT03284424 2024-08-23

MK-3475-629

Phase 2 Completed

159 enrolled 16 charts 2 FDA

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Squamous Cell

NCT03664024 2024-08-22

KEYNOTE-782

Phase 2 Completed

118 enrolled 14 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Adenocarcinoma, Carcinoma, Non-Small-Cell Lung

NCT04152863 2024-08-06

V937-011

Phase 2 Terminated

85 enrolled 19 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Melanoma

NCT02460198 2023-07-27

KEYNOTE-164

Phase 2 Completed

124 enrolled 15 charts

Gastrointestinal

Parkinson Disease 4, Autosomal Dominant Lewy Body, Colorectal Neoplasms

NCT02576990 2023-07-27

MK-3475-170

Phase 2 Completed

80 enrolled 19 charts 1 FDA

Parkinson Disease 4, Autosomal Dominant Lewy Body

NCT02853344 2023-04-11

MK-3475-427

Phase 2 Completed

275 enrolled 16 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Renal Cell

NCT02335424 2023-03-02

MK-3475-052

Phase 2 Completed

374 enrolled 37 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Urinary Bladder Neoplasms

NCT02559687 2022-09-14

KEYNOTE-180

Phase 2 Completed

121 enrolled 14 charts 1 FDA

Gastrointestinal

Parkinson Disease 4, Autosomal Dominant Lewy Body, Esophageal Neoplasms

NCT02335411 2022-08-08

KEYNOTE-059

Phase 2 Completed

318 enrolled 24 charts 1 FDA

Gastrointestinal

Parkinson Disease 4, Autosomal Dominant Lewy Body, Stomach Neoplasms

NCT02968940 2022-06-29

Avelumab With Hypofractionated Radiation Therapy in Adults With Isocitrate Dehydrogenase (IDH) Mutant Glioblastoma

Phase 2 Completed

6 enrolled 10 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Glioblastoma, Glioma

NCT02255097 2022-06-28

Study of MK-3475 (Pembrolizumab) in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma After Treatment With Platinum-based and Cetuximab Therapy (MK-3475-055/KEYNOTE-055)

Phase 2 Completed

172 enrolled 27 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Squamous Cell Carcinoma of Head and Neck

NCT02674061 2022-03-24

KEYNOTE-100

Phase 2 Completed

376 enrolled 102 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Ovarian Neoplasms

NCT02549209 2022-03-02

Pembro/Carbo/Taxol in Endometrial Cancer

Phase 2 Completed

46 enrolled 13 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Endometrial Neoplasms

NCT03322566 2022-01-24

A Study of Pembrolizumab Plus Epacadostat With Platinum-based Chemotherapy Versus Pembrolizumab Plus Platinum-based Chemotherapy Plus Placebo in Metastatic Non-Small Cell Lung Cancer (KEYNOTE-715-06/ECHO-306-06)

Phase 2 Completed

233 enrolled 16 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT02447003 2020-12-16

Study of Pembrolizumab (MK-3475) Monotherapy for Metastatic Triple-Negative Breast Cancer (MK-3475-086/KEYNOTE-086)

Phase 2 Completed

254 enrolled 22 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Breast Neoplasms

NCT01704287 2020-05-18

KEYNOTE 002

Phase 2 Completed

540 enrolled 20 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Melanoma